IDEA AG develops therapeutics using self-optimising carriers for targeted and non-invasive delivery of drugs, including proteins.The Company’s, clinically late stage, leading products are in the area of pain and dermatology. The proprietary carriers, Transfersomes®, are typically applied on the skin and can be engineered to achieve high drug concentration at or near the site of application, diminish local or systemic adverse side effects, and often increase drug potency.